Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

Narayan, Gopeshwar; Houldsworth, Jane; Bacik, Jennifer; Dobrzynski, Deborah; Assaad, Adel; Mansukhani, Mahesh M.; Reuter, Victor; Bosl, George; Chaganti, Raju; Vundavalli, Murty V.; Koul, Sanjay; McKiernan, James M.

Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. The genetic pathway(s) that determine the chemotherapy sensitivity in GCT remain largely unknown. We studied epigenetic changes in relation to cisplatin response by examining promoter hypermethylation in a cohort of resistant and sensitive GCTs. Here, we show that promoter hypermethylation of RASSF1A and HIC1 genes is associated with resistance. The promoter hypermethylation and/or the down-regulated expression of MGMT is seen in the majority of tumors. We hypothesize that these epigenetic alterations affecting MGMT play a major role in the exquisite sensitivity to cisplatin, characteristic of GCTs. We also demonstrate that cisplatin treatment induce de novo promoter hypermethylation in vivo. In addition, we show that the acquired cisplatin resistance in vitro alters the expression of specific genes and the highly resistant cells fail to reactivate gene expression after treatment to demethylating and histone deacetylase inhibiting agents. Our findings suggest that promoter hypermethylation of RASSF1A and HIC1 genes play a role in resistance of GCT, while the transcriptional inactivation of MGMT by epigenetic alterations confer exquisite sensitivity to cisplatin. These results also implicate defects in epigenetic pathways that regulate gene transcription in cisplatin resistant GCT.


  • thumnail for binary/octet-stream 1.07 MB Download File

Also Published In

Molecular Cancer

More About This Work

Academic Units
Irving Comprehensive Cancer Center
Pathology and Cell Biology
BioMed Central
Published Here
September 8, 2014